CONSORZIO ONCOTECH
- Country
- 🇮🇹Italy
- Ownership
- Private
- Established
- 2001-01-01
- Employees
- -
- Market Cap
- -
Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 122
- Registration Number
- NCT05833919
- Locations
- 🇮🇹
Università Campus Biomedico, Roma, Italy
🇮🇹Istituto Nazionale dei Tumori - Fondazione G. Pascale, Napoli, Italy
🇮🇹ASUFC P.O. "Santa Maria della Misericordia", Udine, Italy
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 118
- Registration Number
- NCT05817903
- Locations
- 🇮🇹
Casa Di Cura La Maddalena S.P.A., Palermo, Italy
🇮🇹Ospedale di Belcolle, Viterbo, Italy
🇮🇹ASST degli Spedali Civili di Brescia, Brescia, Italy
Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy
- Conditions
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 300
- Registration Number
- NCT05754502
- Locations
- 🇮🇹
Nuovo ospedale di Prato - S. Stefano, Prato, Firenze, Italy
🇮🇹IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
🇮🇹A.O.U. Ospedali Riuniti Umberto I, Ancona, Italy
Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial)
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 48
- Registration Number
- NCT05735392
- Locations
- 🇮🇹
I.R.C.C.S. A.O.U San Martino - IST, Genova, Italy
🇮🇹A.O. Ospedale Papa Giovanni XXIII - Oncologia, Bergamo, Italy
🇮🇹A.O.U. Policlinico di Modena, Modena, Italy
Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients
- Conditions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 600
- Registration Number
- NCT05730647
- Locations
- 🇮🇹
Centro di Riferimento Oncologico- IRCCS, Aviano, Italy
🇮🇹A.O. Consorziale Policlinico di Bari, Bari, Italy
🇮🇹IRCCS Istituto Oncologico di Bari, Bari, Italy
Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 81
- Registration Number
- NCT05578664
- Locations
- 🇮🇹
Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, RM, Italy
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 49
- Registration Number
- NCT05266937
- Locations
- 🇮🇹
Centro di Riferimento oncologico, Aviano, Pordenone, Italy
🇮🇹Istituto Nazionale dei Tumori - Fondazione G. Pascale U.O. Oncologia Medica Senologica, Napoli, Italy
🇮🇹Arcispedaliera S. Anna di Ferrara U.O. Oncologia Clinica, Ferrara, Italy
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 75
- Registration Number
- NCT04698213
- Locations
- 🇮🇹
ASL CN2 Alba-Bra, Alba, Italy
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
🇮🇹Irccs Istituto in Tecnologie Avanzate E Modelli Assistenziali in Oncologia Di Reggio Emilia, Reggio Emilia, Italy
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 168
- Registration Number
- NCT04318223
- Locations
- 🇮🇹
Istituto Nazionale Tumori Regina Elena (IRE, Roma, Italy
🇮🇹Università degli Studi di Napoli "Federico II", Napoli, Italy
🇮🇹Nuovo ospedale di Prato - S. Stefano, Prato, Firenze, Italy
Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin
- Conditions
- Interventions
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 261
- Registration Number
- NCT04201769
- Locations
- 🇮🇹
Ospedale Civile SS. Annunziata, Sassari, Italy
🇮🇹Istituto Nazionale Tumori "Regina Elena", Roma, Italy
🇮🇹Ospedale Umberto I - RAO SR, Siracusa, Italy